Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBITDA Margin for 2 consecutive years, with 33182.14% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 33182.14% in Q3 2025 year-over-year; TTM through Sep 2025 was 14170.89%, a 1068789.0% decrease, with the full-year FY2023 number at 252.64%, changed N/A from a year prior.
  • EBITDA Margin was 33182.14% for Q3 2025 at Mereo BioPharma, up from 1593.8% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 33182.14% in Q3 2025 to a low of 1593.8% in Q2 2025.